Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
926 Results for "
Lymphomas
" in MedChemExpress (MCE) Product Catalog:
Products (926)
926 Results for "Lymphomas" in MCE Product Catalog:
Cat. No.: HY-13614
CAS No.: 610787-07-0
Target:
Research Areas:
E7974 is a selective inhibitor of α-tubulin (α-tubulin) with an IC50 of 3.9 μM. E7974 disrupts mitotic spindle formation, induces G2-M phase cell cycle arrest, initiates apoptosis, activates caspase-3, and induces poly (ADP-ribose) polymerase cleavage. E7974 reduces the area of choroidal neovascularization in mouse models, and exerts anti-angiogenic effects when loaded in modified micelles. E7974 can be used in research related to cancer and choroidal neovascularization .
Cat. No.: HY-76652
CAS No.: 1264191-73-2
Target:
Research Areas:
VTP-27999 Hydrochloride is an orally active renin inhibitor. VTP-27999 Hydrochloride functionally inhibits renin and acid-activated prorenin, suppresses plasma renin activity and modulates plasma and urinary aldosterone levels. VTP-27999 Hydrochloride reduces mean arterial blood pressure, induces plasma renin concentration increases, decreases plasma angiotensin II levels and enhances renin immunoreactivity. VTP-27999 (Hydrochloride) can be used for the research of hypertension and chronic renal disease .
Cat. No.: HY-N9865
CAS No.: 155899-92-6
Target:
Cat. No.: HY-P99014A
Target:
Research Areas:
Cat. No.: HY-P99983
Target:
Research Areas:
Cat. No.: HY-W011303R
CAS No.: 554-62-1
Synonyms: 4-Hydroxysphinganine (Standard)
Cat. No.: HY-187706
CAS No.: 951529-42-3
Target:
Research Areas:
CDL36 is a BAX inhibitor with an EC50 of 23.6 µM. CDL36 inhibits pro-apoptotic peptide-induced mitochondrial outer membrane permeabilization (MOMP). CDL36 exerts cytoprotective effects against Doxorubicin (HY-15142A)-induced cell death .
Cat. No.: HY-P11306
CAS No.: 247068-92-4
Target:
Research Areas:
Cat. No.: HY-L075
3,061 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
Target:
Research Areas:
Triallate is a selective thiocarbamate herbicide. Triallate regulates the biosynthesis of very-long-chain fatty acids and inhibits the elongation and division of plant cells. Triallate is used to control wild oats in barley, spring wheat, durum wheat, winter wheat and sugar beets .
Cat. No.: HY-181234
CAS No.: 828292-11-1
Y502-3888 is a c-Myc inhibitor. Y502-3888 binds to the c-Myc G4 structure, inhibits c-Myc transcription, and downregulates c-Myc expression at both mRNA and protein levels. Y502-3888 inhibits the viability of myeloma cells and induces cell apoptosis. Y502-3888 can be used for the research of multiple myeloma .
Cat. No.: HY-P992433
OR502 is a humanized IgG1 monoclonal antibody targeting LILRB2 (ILT4/CD85d), with a Kd value of 1.18 nM. OR502 binds to LILRB2 with high affinity and blocks its interaction with HLA class I ligands, relieving myeloid cell-mediated immunosuppression, restoring CD8 + T cell function, and reprogramming the immunosuppressive macrophage phenotype, thereby simultaneously enhancing both innate and adaptive antitumor immune responses. OR502 can be used in the research of cancers and advanced cancers (including melanoma, non-small cell lung cancer, sarcoma/soft tissue cancer, and urothelial carcinoma) .
Target:
Research Areas:
Glutaminase (GLS) is a metabolic enzyme. Glutaminase catalyzes the conversion of glutamine to glutamate, which is a key step in glutaminolysis. The glutaminase isoenzymes GLS and GLS2 differ in their expression patterns and functional roles: GLS exhibits oncogenic properties, whereas GLS2 is regarded as a tumor suppressor. Glutaminase expression levels correlate with the degree of tumor malignancy .
Cat. No.: HY-172889
CAS No.: 3085191-45-0
PI3K/HDAC-IN-4 (Compound 31f) is a PI3K/HDAC dual inhibitor (IC50: 0.2μM). PI3K/HDAC-IN-4 shows high selectivity for HDAC1-3 (IC50 values of 75.5 nM, 70.9 nM, and 1.9 nM, respectively). PI3K/HDAC-IN-4 is a potent PIK3 inhibitor with IC50 values of 2.5 nM, 80.5 nM, 10.0 nM, and 57.2 nM for PI3Kα, β, δ, and γ, respectively. PI3K/HDAC-IN-4 significantly induces tumor cell apoptosis by simultaneously inhibiting the PI3K/AKT/mTOR signaling pathway and HDAC1-3. PI3K/HDAC-IN-4 exhibits potent antiproliferative activity in a variety of tumor cell lines (e.g., MV4-11, Jeko-1, HL60, and MCF-7, with IC50 values of 0.2, 0.9, 0.8, and 1.5 μM, respectively). PI3K/HDAC-IN-4 can be used in the study of lymphoma and leukemia .
Cat. No.: HY-181565
CAS No.: 2640208-32-6
Target:
Research Areas:
CDK7-IN-33 is an orally active pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases .
Cat. No.: HY-181174
CAS No.: 2996086-75-8
Research Areas:
Antioxidant agent-22 is a paraben derivative tetracyclic spermine cyclotriphosphazene compound. Antioxidant agent-22 exhibits antioxidant, anti-Inflammatory, and apoptotic activities. Antioxidant agent-22 significantly upregulates CAT, SOD, caspase-3 and IL-6 expression, suppresses GSH, IL-1β, and reduces BCL-2 and BAX levels. Antioxidant agent-22 can be used for the research of cancer, such as lung cancer .
Target:
Research Areas:
Acedoben is a biochemical reagent. Acedoben can form a rapidly self-assembled coordination complex with iron ions. The Fe-Ace coordination complex not only serves as a carrier for tumor antigens, but also enhances antigen-specific anti-tumor immunity due to its inherent adjuvant properties .
Cat. No.: HY-B1250A
CAS No.: 29305-16-6
Target:
Research Areas:
Acedoben sodium is a biochemical reagent. Acedoben sodium can form a rapidly self-assembled coordination complex with iron ions. The Fe-Ace coordination complex not only serves as a carrier for tumor antigens, but also enhances antigen-specific anti-tumor immunity due to its inherent adjuvant properties .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
